| 000 | 01154 a2200349 4500 | ||
|---|---|---|---|
| 005 | 20250513150835.0 | ||
| 264 | 0 | _c19981022 | |
| 008 | 199810s 0 0 eng d | ||
| 022 | _a0362-5664 | ||
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aHead, J | |
| 245 | 0 | 0 |
_aReply to Jack E. Riggs' "Deprenyl, excess mortality, and epidemiological traps". Parkinson's Disease Research Group of the United Kingdom. _h[electronic resource] |
| 260 |
_bClinical neuropharmacology _c |
||
| 300 |
_a265-6 p. _bdigital |
||
| 500 | _aPublication Type: Comment; Letter | ||
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 | _aAge Factors |
| 650 | 0 | 4 | _aAged |
| 650 | 0 | 4 | _aAged, 80 and over |
| 650 | 0 | 4 |
_aAntiparkinson Agents _xtherapeutic use |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aLevodopa _xtherapeutic use |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 |
_aParkinson Disease _xdrug therapy |
| 650 | 0 | 4 | _aProportional Hazards Models |
| 650 | 0 | 4 | _aRandomized Controlled Trials as Topic |
| 650 | 0 | 4 |
_aSelegiline _xtherapeutic use |
| 650 | 0 | 4 | _aTreatment Outcome |
| 700 | 1 | _aBen-Shlomo, Y | |
| 700 | 1 | _aLees, A J | |
| 773 | 0 |
_tClinical neuropharmacology _gvol. 21 _gno. 4 _gp. 265-6 |
|
| 999 |
_c9669777 _d9669777 |
||